Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library
© Zhou et al.; licensee BioMed Central Ltd. 2012
Received: 26 November 2011
Accepted: 9 July 2012
Published: 9 August 2012
While there is strong evidence for phosphatidylinositol 3-kinase (PI3K) involvement in cancer development, there is limited information about the role of PI3K regulatory subunits. PIK3R3, the gene that encodes the PI3K regulatory subunit p55γ, is over-expressed in glioblastoma and ovarian cancers, but its expression in gastric cancer (GC) is not known. We thus used genetic and bioinformatic approaches to examine PIK3R3 expression and function in GC, the second leading cause of cancer mortality world-wide and highly prevalent among Asians.
Primary GC and matched non-neoplastic mucosa tissue specimens from a unique Asian patient gastric cancer library were comprehensively profiled with platforms that measured genome-wide mRNA expression, DNA copy number variation, and DNA methylation status. Function of PIK3R3 was predicted by IPA pathway analysis of co-regulated genes with PIK3R3, and further investigated by siRNA knockdown studies. Cell proliferation was estimated by crystal violet dye elution and BrdU incorporation assay. Cell cycle distribution was analysed by FACS.
PIK3R3 was significantly up-regulated in GC specimens (n = 126, p < 0.05), and 9.5 to 15% tumors showed more than 2 fold increase compare to the paired mucosa tissues. IPA pathway analysis showed that PIK3R3 promoted cellular growth and proliferation. Knockdown of PIK3R3 decreased the growth of GC cells, induced G0/G1 cell cycle arrest, decreased retinoblastoma protein (Rb) phosphorylation, cyclin D1, and PCNA expression.
Using a combination of genetic, bioinformatic, and molecular biological approaches, we showed that PIK3R3 was up-regulated in GC and promoted cell cycle progression and proliferation; and thus may be a potential new therapeutic target for GC.
Class IA Phosphatidylinositol 3’-kinases (PI3K) is a heterodimer that consists of a p110 catalytic subunit and a p85 regulatory subunit. The catalytic subunit isoforms p110α, p110β and p110δ are encoded by three genes — PIK3CA, PIK3CB and PIK3CD, respectively . The role of catalytic subunits in a wide range of cellular processes associated with cancer development and progression is well established . The PIK3CA gene is one of the best studied oncogenes, and is amplified, overexpressed, or frequently mutated in many cancers, including GC [2, 3]. PIK3CB is the principal isoform involved in mediating PTEN-deficient tumourigenesis . In addition, PIK3CD has also emerged as a key therapeutic target for haematological malignancies , notably acute myeloid leukaemia (AML). Consequently, targeting catalytic subunits represents an important strategy for the development of novel cancer therapeutics.
In contrast, current understanding of the role of regulatory subunits in tumorigenesis has been limited. Three genes, PIK3R1, PIK3R2 and PIK3R3, encode the p85α, p85β and p55γ isoforms of the p85 regulatory subunit, respectively . PIK3R1, the inhibitory subunit of PI3K, is mutated in primary colorectal and endometrial cancer tumors [7, 8], and ectopic expression of some of those mutations increased the pAKT level in U2OS cells. Interestingly, PIK3R3 has increased expression in glioblastoma multiforme and ovarian cancer [9, 10]. Knockdown of PIK3R3 inhibits IGF2-induced cell growth in glioblastoma multiforme  and induces apoptosis in ovarian cancer cells . Taken together, these results suggest an oncogenic role for PIK3R3 in these cancers.
GC is the second leading cause of global cancer mortality and is highly prevalent among Asians . Most GC patients are diagnosed with late stage disease and the overall 5-year survival rate is <24% [12–14]. Deregulation of canonical oncogenic pathways such as E2F, K-RAS, p53, and Wnt/b-catenin signaling are known to occur with varying frequencies in GC [15–17], suggesting that GC is a heterogeneous disease with multiple molecular defects. Although PIK3R3 is overexpressed in several cancers, little is known about the expression and functional role of PIK3R3 in GC. To address these issues, we used genetic and bioinformatic approaches to interrogate a unique library of 126 paired GC samples and matched non-neoplastic mucosa tissues from Asian GC patients.
Human cancer specimens and cell lines
We created a library of 126 primary gastric tumors and their matched non-neoplastic mucosa tissues from 126 Asian patients that were originally stored at the SingHealth Tissue Repository, an institutional resource of National Cancer Centre of Singapore and Singapore General Hospital. All patient samples were obtained with informed patient consent and approvals from Institutional Review Boards and Ethics Committees. GC cell lines HGC-27, KATO III, AGS cells were purchased from the American Type Culture Collection. MKN7, TMK1 and IM95 cells were obtained from the Japan Health Science Research Resource Bank. Cell lines were maintained in a humidified atmosphere containing 5% CO2 at 37°C. HGC-27, IM95 cells were cultured in DMEM medium supplemented with 10% FBS (Sigma); AGS, TMK1 and KATO III and MKN7 were cultured in RPMI 1640 medium supplemented with 10% FBS.
Microarray Profiling & Pre-processing
Genomic DNA was extracted from flash-frozen tissues using a Qiagen genomic DNA extraction kit. Total RNAs was extracted using Trizol (Invitrogen, CA), digested with RNase free DNase (RQ1 DNase, Promega), and subsequently purified using an RNeasy Mini kit (Qiagen,CA). Genome-wide mRNA expression was profiled using Affymetrix GeneChip Human Genome U133 Plus 2.0 array. Copy number analysis was profiled using Affymetrix Human SNP array 6.0. DNA methylation analysis was profiled using Illumina Infinium methylation assay. Profiling on the individual microarray platforms was done according to manufacturer’s specifications.
The raw microarray data was pre-processed using the respective platform software from the manufacturer: mRNA and SNP data using Affymetrix’s Genome Studio and Genotyping Console respectively, and DNA methylation using Illumina’s BeadStudio. For SNP data, the normal gastric samples were used as the reference for normalization. The copy number segmentation was generated using Circular Binary Segmentation (CBS) from the R package DNA copy  using default settings. Gene-based copy number alterations were obtained by averaging the segments within each gene. Amplification and deletion were called using the threshold of 0.3 and −0.3 respectively .
The microarray data has been deposited into the National Centre for Biotechnology Information’s (NCBI) Gene Expression Omnibus (GEO) website, series accession number GSE31168 (SNP6) and GSE15460 (mRNA).
PIK3R3 co-regulated gene and IPA pathway analysis
Co-regulated genes with PIK3R3 were elucidated using Pearson correlation on the mRNA data. We focused on probes that were specifically targeting the genes (i.e., probes with suffix ‘_at’ and ‘_a_at’) and significant correlation after correcting for multiple testing (p < 1e-5). Pathways involving the probes were assessed using Ingenuity Pathway Analysis software (http://www.ingenuity.com). All statistical analyses were computed using the R statistical package.
RNA Extraction and RT-PCR
Total cellular RNA was isolated with the High Pure RNA isolation Kit (Roche) following the manufacturer's protocol and total RNA was quantified with a Nanodrop ND-1000 spectrophotometer. Total RNA (1 μg) was reverse-transcribed using iSCRIPT cDNA synthesis kit (Bio-rad) under condtions defined by the supplier. cDNA was quantified by real-time PCR on the Rotor-Gene Q System (Qiagen). PIK3R3 forward primer: GAGAGGGGAATGAAAAGGAGA, and reverse primer: ATCATGAATCTCACCCAGACG . β-actin forward primer: AGAGCCTCGCCTTTGCCGAT, and reverse primer: TTGCACATGCCGGAGCCGTT; GAPDH forward primer: TCTTTTGCGTCGCCAGCCGA, and reverse primer: CCAGGCGCCCAATACGACCA. PCR was done using QuantiFast SYBR Green PCR Kit (Qiagen) according to manufacturer’s instructions.
To test the effect of LY294002 on PIK3R3 expression, the complete medium was replaced by serum free medium and LY294002 (20 μM/L, Sigma) was added. The total RNA was extracted 24 h after LY294002 treatment.
PIK3R3 siRNA transfection
Two PIK3R3 siRNAs ordered from Santa Cruz (sc-39124) or Invitrogen (s16152) were used to knock down PIK3R3 in GC cells. HGC-27 or TMK1 cells were seeded into 12 or 6-well plates in complete medium and cultured overnight. Then the medium was replaced with opti-MEM medium (Invitrogen) containing PIK3R3 or control siRNA and Lipofectamine RNAimax (Invitrogen) according to the manufacturer’s recommendations. 48 h after transfection, cell lysates were prepared for Western blot analysis for detection of PIK3R3 expression.
Cell proliferation assay
Cell proliferation assay was done as previously described [20, 21]. Briefly, 24 h after siRNA transfection, the HGC27 cells were trypsinized, resuspended in 1.1 ml complete culture medium, and re-seeded into 4 new 12-well plates at 250 μl per well. The cells were fixed 1 to 4 days after re-seeding, respectively, and stained with crystal violet. Using 10% acetic acid, dye was extracted, and absorbance at 595 nm was measured using a multiwall spectrophotometer (Bio-Rad).
Measurement of BrdU incorporation
48 h after siRNA transfection, HGC27 cells cultured in 6 well-plates were incubated with BrdU (10 μg/ml) for 7 min. The cells were detached, fixed and stained using FITC BrdU Flow Kit (BD Pharmingen) following the manufacturer's protocol. DNA synthesis was determined by flow cytometer.
Annexin-V/propidium iodide staining
Annexin V staining was detected by flow cytometry using the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen). 48 h after siRNA transfection, Both floating and adherent HGC27 cells were collected. Then the cells were washed and stained following the manufacturer's protocol. Apoptotic cells were determined by flow cytometer.
Cell cycle analysis
48 h after siRNA transfection, HGC-27 cells were harvested, washed twice with cold phosphate buffered saline (PBS, pH 7.4), and fixed with 70% ethanol/30% PBS at 4°C overnight. The fixed cells were incubated with 0.5 ml PBS containing 10 μg/ml RNase for 30 min at 37°C, then stained with 20 μg/ml propidium iodide (PI, Sigma) for 30 min in the dark at room temperature, and finally analyzed on a FACS cytometer (Beckman FC5000). A minimum of 1 × 104 cells/sample was evaluated.
Western blot analysis
Cells were harvested, and lysed 48 h after siRNA transfection. Proteins were separated by SDS–PAGE under reducing conditions and transferred to nitrocellulose membranes. Membranes were blocked with 5% nonfat milk in phosphate-buffered saline with 0.1% tween 20 (PBST), and the membranes for PI3KR3 blot were blocked with 2% gelatine, 0.2% FBS in PBST . The blots were incubated overnight at 4°C with the following antibodies: anti-PIK3R3 antibody, anti-beta actin antibody (Santa Cruz), anti-phospho-RB (Ser 780), anti-cyclin D1, anti- phospho-p38 MAPK antibody (Thr180/Tyr 182), anti-phospho-AKT (Ser 473), anti-phospho-AKT (Ser 308), anti-phospho-m-TOR (Ser 2448) (Cell signaling Technology), anti-PCNA antibody (Millipore). Immunoblot analysis was performed using an enhanced chemiluminescence procedure (GE Healthcare).
PIK3R3 mRNA is over-expressed in a subgroup of GC
Knockdown of PIK3R3 expression decreases cell proliferation in GC cells
Knockdown of PIK3R3 causes G0/G1 cell cycle arrest
Knockdown of PIK3R3 decreases Rb phosphorylation and cyclin D1 protein expression but does not affect basal pAkt level
To understand better the functional role of PIK3R3 on cell proliferation, we examined the expression of various molecular markers in the PIK3R3 knockdown cells. We found reduced cyclin D1 levels and decreased phosphorylation of Rb protein, both of which are associated with G0/G1 arrest (Figure 3B and Additional file 3: Figure S3B). Expression of the cell proliferation marker, PCNA, also was reduced (Figure 3B). Interestingly, phosphorylation of Akt and mTOR was unaffected by PIK3R3 knockdown (Figure 3B and Additional file 3: Figure S3), suggesting that over-expression of PIK3R3 does not primarily drive cell proliferation through PI3K-pAkt signaling.
PIK3R3 over-expression can be regulated by PIK3CA
Although the roles of the PI3K catalytic subunit in tumorigenesis is well established, current understanding of the function of PI3K regulatory subunits such as PIK3R3 is still limited. A previous study showed that PIK3R3 gene had copy number gain in high-grade glioma, and the Comparative Genomic Hybridization (CGH) ratios for this locus were positively-correlated with proliferation signatures . Furthermore, the IGF2-PIK3R3 signaling axis was involved in promoting the growth of a subclass of highly aggressive human glioblastomas . In this study, we compared PIK3R3 expression in 126 paired GC with non-neoplastic gastric mucosa control tissues from the same patients, and found that approximately 9.5% to 15% of GC showed increased PIK3R3 expression. IPA pathway analysis suggested a key role of PIK3R3 in cell proliferation. Knockdown of PIK3R3 by siRNA decreased HGC27 GC cell proliferation and induced cell cycle blockade at G0/G1. Taken together, these results suggest that PIK3R3 stimulates cell proliferation in GC and may be a potential therapeutic target for a subgroup of GC.
PIK3R3 shares significant sequence identity with PIK3R1 and PIK3R2 regulatory subunit in a proline-rich motif and two Src homology 2 (SH2) domains; however, it has an unique 24-residue NH2 terminus . PIK3R3 binds to Rb via this unique region as the N-terminal 24 amino acids of PIK3R3 (N24) are sufficient for binding to Rb [27, 28]. Ectopic expression of N24 also inhibited cyclin D1 and E promoter activity and caused G0/G1 phase arrest in several cancer cell lines . Likewise, in the current study, knockdown of PIK3R3 caused G0/G1 cell cycle arrest in HGC27 and TMK1 GC cells. Consistent with this observation, Rb phosphorylation, cyclin D1, and PCNA protein levels also were decreased after PIK3R3 knockdown. Interestingly, the pAkt levels did not change after PIK3R3 knockdown. Additionally, when PIK3R3 was overexpressed in AGS cells, a low PIK3R3-expressing gastric cancer cell line, we did not observe any significant change in phosphorylation of Akt (data not shown). Taken together, these findings show that both increased and decreased expression of PIK3R3 do not affect pAkt levels in these cell lines under our experimental conditions. Of note, we have observed similar effects in several colon cancer cell lines and MCF7 breast cancer cells (and unpublished data). This lack of change in pAkt levels may be due to either preferential nuclear localization of PIK3R3  or low PIK3R3 expression relative to p85 regulatory subunit isoforms. In contrast to our findings, Soroceau et al. found decreased pAkt in G96 glioblastoma cells after PIK3R3 knockdown which may be due to different experimental conditions or different tissue origins of cell lines as PIK3R3 expression is high in the brain . Nevertheless, our current and previous studies suggest that PIK3R3 can promote cell growth through a novel signaling pathway by regulating Rb phosphorylation and cyclin D1.
Finally, we investigated the mechanism of PIK3R3 over-expression in GC. Zhang et al. found PIK3R3 was over-expressed in ovarian cancer due to gene copy number gain . However, no gene amplification or DNA de-methylation of PIK3R3 gene was found in our set of GC samples. Interestingly, Demoulin et al. found that PDGF activated transcription factor SREBP-1 in a PI3K-dependent manner , and ectopic expression of SREBP-1 induces the expression of PIK3R3 in AG01518 human foreskin fibroblasts . Therefore, these results suggested that activated PI3K signaling could induce the expression of PIK3R3. Indeed, we observed a positive correlation between PIK3CA and PIK3R3 mRNA expression in our 126 GC samples. Furthermore, the PIK3CA inhibitor, LY294002 decreased PIK3R3 expression in HGC27 and IM95 GC cell lines. Our results thus provide direct experimental evidence that PIK3R3 expression can be regulated by PIK3CA.
The in silico and molecular biological approaches used in the present study have provided a better understanding of the expression and role of PIK3R3 in GC. The identification of PIK3R3 as a proliferation-promoting factor in GC suggests that it might be a potential therapeutic target for a subset of GC.
acute myeloid leukaemia
Circular Binary Segmentation
phosphate-buffered saline with 0.1% Tween 20
Comparative Genomic Hybridization
Src homology 2
N-terminal 24 amino acid of PIK3R3.
The authors would like to thank Mr. Sherwin Ying Xie, Dr. Mobin M. Siddique (Cardiovascular and Metabolic Disorders Program, Duke-NUS Graduate Medical School) for their helpful advice and constructive criticisms. This work was supported by NMRC and Duke-NUS Graduate Medical School Faculty Funds sponsored by the Ministry of Health, Ministry of Education, and Ministry of Trade, Singapore and A*StaR to PMY and PT, and Khoo Discovery Award (KDP/2008/0002 and KDP/2009/0006) to LKG.
- Fruman DA, Meyers RE, Cantley LC: Phosphoinositide kinases. Annu Rev Biochem. 1998, 67: 481-507. 10.1146/annurev.biochem.67.1.481.View ArticlePubMedGoogle Scholar
- Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005, 5 (12): 921-929. 10.1038/nrc1753.View ArticlePubMedGoogle Scholar
- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304 (5670): 554-10.1126/science.1096502.View ArticlePubMedGoogle Scholar
- Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C: PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA. 2008, 105 (35): 13057-13062. 10.1073/pnas.0802655105.View ArticlePubMedPubMed CentralGoogle Scholar
- Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B, Khwaja A: A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene. 2006, 25 (50): 6648-6659. 10.1038/sj.onc.1209670.View ArticlePubMedGoogle Scholar
- Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006, 7 (8): 606-619. 10.1038/nrg1879.View ArticlePubMedGoogle Scholar
- Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, et al: Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell. 2009, 16 (6): 463-474. 10.1016/j.ccr.2009.10.016.View ArticlePubMedPubMed CentralGoogle Scholar
- Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW: PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011, 71 (12): 4061-4067. 10.1158/0008-5472.CAN-11-0549.View ArticlePubMedPubMed CentralGoogle Scholar
- Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, et al: Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci USA. 2007, 104 (9): 3466-3471. 10.1073/pnas.0611271104.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O'Brien-Jenkins A, Katsaros D, et al: Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res. 2007, 13 (18 Pt 1): 5314-5321.View ArticlePubMedGoogle Scholar
- Devesa SS, Bray F, Vizcaino AP, Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005, 117 (2): 294-299. 10.1002/ijc.21183.View ArticlePubMedGoogle Scholar
- Sun W, Haller DG: Recent advances in the treatment of gastric cancer. Drugs. 2001, 61 (11): 1545-1551. 10.2165/00003495-200161110-00002.View ArticlePubMedGoogle Scholar
- Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000, 87 (2): 236-242. 10.1046/j.1365-2168.2000.01360.x.View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66. 10.3322/canjclin.57.1.43.View ArticlePubMedGoogle Scholar
- Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E: Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 1999, 81 (4): 535-538. 10.1002/(SICI)1097-0215(19990517)81:4<535::AID-IJC5>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, Yoshihara M, Shimamoto F, Chayama K: K-ras mutation in helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Cancer. 2002, 97 (5): 562-566. 10.1002/ijc.1644.View ArticlePubMedGoogle Scholar
- Chen XY, Wang ZC, Li H, Cheng XX, Sun Y, Wang XW, Wu ML, Liu J: Nuclear translocations of beta-catenin and TCF4 in gastric cancers correlate with lymph node metastasis but probably not with CD44 expression. Hum Pathol. 2005, 36 (12): 1294-1301.PubMedGoogle Scholar
- Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004, 5 (4): 557-572. 10.1093/biostatistics/kxh008.View ArticlePubMedGoogle Scholar
- Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, et al: Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007, 104 (50): 20007-20012. 10.1073/pnas.0710052104.View ArticlePubMedPubMed CentralGoogle Scholar
- Gayer CP, Chaturvedi LS, Wang S, Craig DH, Flanigan T, Basson MD: Strain-induced proliferation requires the phosphatidylinositol 3-kinase/AKT/glycogen synthase kinase pathway. J Biol Chem. 2009, 284 (4): 2001-2011.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou J, Chen Y, Lang JY, Lu JJ, Ding J: Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling. Mol Cancer Res. 2008, 6 (2): 194-204. 10.1158/1541-7786.MCR-07-0197.View ArticlePubMedGoogle Scholar
- Kivi N, Greco D, Auvinen P, Auvinen E: Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene. 2008, 27 (18): 2532-2541. 10.1038/sj.onc.1210916.View ArticlePubMedGoogle Scholar
- Demoulin JB, Ericsson J, Kallin A, Rorsman C, Ronnstrand L, Heldin CH: Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J Biol Chem. 2004, 279 (34): 35392-35402. 10.1074/jbc.M405924200.View ArticlePubMedGoogle Scholar
- Kallin A, Johannessen LE, Cani PD, Marbehant CY, Essaghir A, Foufelle F, Ferre P, Heldin CH, Delzenne NM, Demoulin JB: SREBP-1 regulates the expression of heme oxygenase 1 and the phosphatidylinositol-3 kinase regulatory subunit p55 gamma. J Lipid Res. 2007, 48 (7): 1628-1636. 10.1194/jlr.M700136-JLR200.View ArticlePubMedGoogle Scholar
- Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006, 9 (3): 157-173. 10.1016/j.ccr.2006.02.019.View ArticlePubMedGoogle Scholar
- Pons S, Asano T, Glasheen E, Miralpeix M, Zhang Y, Fisher TL, Myers MG, Sun XJ, White MF: The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol. 1995, 15 (8): 4453-4465.View ArticlePubMedPubMed CentralGoogle Scholar
- Xia X, Cheng A, Akinmade D, Hamburger AW: The N-terminal 24 amino acids of the p55 gamma regulatory subunit of phosphoinositide 3-kinase binds Rb and induces cell cycle arrest. Mol Cell Biol. 2003, 23 (5): 1717-1725. 10.1128/MCB.23.5.1717-1725.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- Hu J, Liu S, Wang J, Luo X, Gao X, Xia X, Feng Y, Tao D, Wang G, Li X, et al: Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells. Int J Oncol. 2005, 26 (5): 1321-1327.PubMedGoogle Scholar
- Hu J, Xia X, Cheng A, Wang G, Luo X, Reed MF, Fojo T, Oetting A, Gong J, Yen PM: A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Mol Cancer Ther. 2008, 7 (12): 3719-3728. 10.1158/1535-7163.MCT-08-0499.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1755-8794/5/34/prepub